RxMapper
RxMapper is a Scottsdale-based pharmacogenomics platform that uses DNA sequencing to match patients with optimal medications. Serving employers and health plans as B2B payers, the company delivers PGx-certified pharmacist telehealth consultations developed in collaboration with Mayo Clinic.
- Company typePrivate
- Founded2015
- HeadquartersScottsdale, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What RxMapper does
RxMapper is a Scottsdale, Arizona-based personalized medication platform that uses DNA sequencing and pharmacogenomic (PGx) analysis to match patients with medications most likely to be safe and effective for them. The company was developed over approximately ten years in collaboration with Mayo Clinic and operates as a telehealth consult practice. Its platform sequences over 36 million DNA base pairs per patient and analyzes compatibility against more than 6,500 commercial drugs across 328 medical conditions, with clinical analysis performed by pharmacists PGx-certified through Mayo Clinic's "Integrating Pharmacogenomics into Clinical Practice" certificate program.
The core product consists of three integrated components: a mail-in saliva DNA collection kit, sequencing and PGx analysis, and a telehealth consultation that delivers a personalized medication action plan shared with the patient's broader care team. Patients are sequenced once and their profiles are continuously updated as new drugs and clinical insights emerge. A standalone MyRxMapper patient portal provides secure access to results and consultation scheduling. The platform is SOC 2 Type II certified, HIPAA compliant, and operates in compliance with the Genetic Information Nondiscrimination Act (GINA).
RxMapper operates on a B2B2C model in which employers and health plans are the paying customers while the service is offered as a free benefit to individual employees and members. Primary customer segments are self-insured and fully-insured employers, health insurance plans and PBMs, and benefits brokers/consultants, with a national network of PGx-certified licensed pharmacists serving as the telehealth provider channel across all 50 states. The company is privately held, was co-founded by Jim Miller (CEO), Chris Grilli (Chairman), and David Upjohn (CTO), and has raised approximately $8.2 million in disclosed funding through a single meaningful round in November 2022.
RxMapper firmographics
Firmographics- Name
- RxMapper
- Legal name
- RxMapper, LLC
- Website
- https://rxmapper.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- RxMapper is a Scottsdale-based pharmacogenomics platform that uses DNA sequencing to match patients with optimal medications. Serving employers and health plans as B2B payers, the company delivers PGx-certified pharmacist telehealth consultations developed in collaboration with Mayo Clinic.
- Ownership category
- akta.pro rank
RxMapper industry classification
Industry- Product category
- Pharmacogenomics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Health Services (8000)
- akta.pro primary industry
- Pharmacogenomics (PGx) Decision Support (HLAAANAB)
- akta.pro secondary industries
- Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools (HLACAKAH), Prescription-Based Digital Clinics (Condition-Specific Rx Programs) (HLALAAAD), Healthcare Outcomes & Real-World Evidence (RWE) Analytics (BPAHALAN)
Keywords
Where RxMapper is headquartered
LocationHeadquarters
- HQ city
- Scottsdale
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
RxMapper business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Employer Health Plan B2B Billing: RxMapper bills employer clients directly for DNA collection, sequencing, analysis, and telehealth consultation services. The service is offered as a free employee benefit, with employers paying a per-eligible-employee or per-enrolled-member fee. The revenue model is subscription-like on a per-employee basis, with employers and health plans as the paying customers rather than individual patients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Free for employees; employer pays per employee enrolled |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
RxMapper product offering
Product offeringCore offering
RxMapper provides DNA-based personalized medication analysis by sequencing patient DNA (over 36 million base pairs) and matching it against the safety and efficacy profiles of more than 6,500 commercial drugs across 328 medical conditions. Results are interpreted by pharmacists PGx-certified through Mayo Clinic and delivered to patients via telehealth consultations, with recommendations shared back to the patient's broader care team. The service is sold to employers and health plans on a per-employee subscription basis and offered as a free benefit to their covered members.
Product overview
RxMapper is a personalized medication platform and telehealth consult practice developed in collaboration with Mayo Clinic. The core offering consists of three integrated components: DNA Collection and Sequencing (mailing DNA kits to patients, sequencing over 36 million DNA base pairs), DNA Analysis using pharmacogenomics (analyzing over 6,500 medications for 328 medical conditions), and Telehealth Consultations with Mayo Clinic PGx-certified pharmacists who provide personalized medication recommendations based on each patient's genetic profile. Patients access their results and manage their care through the MyRxMapper patient portal.
Differentiator
Problem solved
Functional benefit
Products and services
- RxMapper Personalized Medication Platform Integrated DNA-based personalized medication service that mails DNA collection kits to patients, sequences over 36 million DNA base pairs per patient once, runs pharmacogenomic analysis against 6,500+ drugs across 328 medical conditions, and delivers a personalized medication action plan through a telehealth consultation with a Mayo Clinic PGx-certified pharmacist, with recommendations shared back to the patient's care team. Sold to employers and health plans as a per-employee subscription and offered to covered employees/members as a free benefit.
- MyRxMapper Patient Portal Secure patient portal where patients access their DNA sequencing results, view their personalized medication profile that is continuously updated with new drug insights, schedule telehealth consultations with RxMapper pharmacists, and manage their healthcare information.
Quantifiable outcome
- Employers can save $35.4M in drug spend (Harvard Pilgrim Health Care case study showing 22% of $159.8M in top-15 drugs was wasted on non-responding patients)
- +4 more outcomes
Companies that use RxMapper
Customer profileNamed customers1 record
Segments5 records
Ideal customer profiles4 records
RxMapper technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
RxMapper partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship, core and minor.
- Mayo ClinicflagshipRxMapper was developed over ten years in collaboration with Mayo Clinic and is described as a clinically and commercially validated solution. Mayo Clinic provides the PGx (pharmacogenomics) certification program that all RxMapper pharmacists complete. The collaboration has produced a proprietary DNA analysis platform that delivers individualized medication insights. This is the foundational partnership upon which RxMapper's clinical credibility and technology are built.
- Harvard Pilgrim Health CarecoreHarvard Pilgrim Health Care partnered with RxMapper for a pilot analysis of their top 15 drug spend ($159.8M). RxMapper found that 22% of this spending was wasted on patients who do not respond to their prescribed drugs. The analysis demonstrated potential savings of $35.4M if all members had been sequenced. This partnership serves as a key case study demonstrating RxMapper's value proposition to health plans.
- PDCM Insurance / Patriot Growth InsuranceminorPDCM Insurance (division of Patriot Growth Insurance) provides benefit advisory services to employers and has partnered with RxMapper to offer personalized medication benefits through their employee benefits practice. Benefit advisors John Monaghan and Liz Frayer serve as RxMapper benefit advisors representing the partnership.
Scale indicators14 records
Recent moves7 records
Expansion highlights5 records
RxMapper competitors and assessment
Company assessmentDirect peers
- OneOme: OneOme delivers pharmacogenomic analysis and clinical decision support for medication selection, co-developed with Mayo Clinic. Most direct comparable on both technology architecture and clinical partnership model.
- Color Health: Color provides population-scale genetic testing and clinical-grade genomic insights, including pharmacogenomics, to employers and health plans. Comparable in B2B employer-benefits DNA model and telehealth delivery.
- Genomind: Genomind is a pharmacogenomics company offering PGx testing and decision support to clinicians and patients, with a similar focus on mental health and specialty medication matching. Directly comparable to RxMapper in core technology and end-customer use case.
- Translational Software (now part of PharmGKB-linked offerings): Translational Software provides PGx clinical decision support integrated into EHR and pharmacy workflows. Closely comparable to RxMapper's pharmacogenomic analysis engine and clinical reporting layer.
- Coriell Life Sciences: Coriell Life Sciences offers pharmacogenomic interpretation and medication management services to employers, health systems, and payers. Highly comparable to RxMapper's PGx-plus-counseling model.
Broad incumbents
- Quest Diagnostics: Quest Diagnostics is a national clinical lab that has expanded into pharmacogenomic testing panels and has deep payer and employer health-program relationships. Competes with RxMapper on PGx lab services and B2B distribution.
- 23andMe: 23andMe provides direct-to-consumer and B2B genetic testing, including some PGx-related reports, and has explored employer-benefit partnerships. Overlaps with RxMapper on consumer DNA and employer-benefit distribution.
- Myriad Genetics: Myriad is an established genetic diagnostics company with pharmacogenomic and oncology offerings, selling into clinicians, payers, and employers. Comparable at the diagnostics layer but operates at much larger scale and broader portfolio.
- GeneDx: GeneDx is a clinical genomics company (now part of Sema4) offering hereditary disease and PGx testing with payer relationships and a national lab. Broader portfolio but overlapping on pharmacogenomic diagnostics.
- Invitae: Invitae is a large medical genetics company offering a broad menu of hereditary and pharmacogenomic tests to clinicians and health systems. Comparable on the lab/sequencing side of RxMapper's offering.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
RxMapper social profiles
Digital presenceRxMapper compliance and trust
Trust signalCompliance2 records
RxMapper financial estimates
Financial estimateRevenue estimate
Valuation estimate
RxMapper leadership team
Management profileNumber of profiles
Profiles3 records
RxMapper funding detail
Funding detailFunding overview
Funding rounds4 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RxMapper M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RxMapper
What does RxMapper do?
RxMapper provides DNA-based personalized medication analysis by sequencing patient DNA (over 36 million base pairs) and matching it against the safety and efficacy profiles of more than 6,500 commercial drugs across 328 medical conditions. Results are interpreted by pharmacists PGx-certified through Mayo Clinic and delivered to patients via telehealth consultations, with recommendations shared back to the patient's broader care team. The service is sold to employers and health plans on a per-employee subscription basis and offered as a free benefit to their covered members.
Is RxMapper a public or private company?
RxMapper is a private company. It is classified as venture growth investor backed and is currently operating.
When was RxMapper founded?
RxMapper was founded in 2015. It employs 11 to 50 people.
Where is RxMapper based?
RxMapper is headquartered in Scottsdale, United States, in the North America region.
How does RxMapper make money?
One revenue line is on record: employer Health Plan B2B Billing.
Who are RxMapper's main competitors?
Direct peers on record are OneOme, Color Health, Genomind, Translational Software (now part of PharmGKB-linked offerings) and Coriell Life Sciences. Broad incumbents are Quest Diagnostics, 23andMe, Myriad Genetics, GeneDx and Invitae.
Does RxMapper have an API?
No public API is recorded for RxMapper.
What industry is RxMapper in?
RxMapper's product category is Pharmacogenomics. Its primary akta.pro industry code is HLAAANAB, Pharmacogenomics (PGx) Decision Support, with a secondary code of HLACAKAH, Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools. Its NAICS code is 621511 and its SIC code is 8071.